

State of Oklahoma SoonerCare Pemazyre[®] (Pemigatinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	1
Pharmacy Billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Inforn	nation
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
Yes No B. Has the member C. Is disease positive rearrangement? Myeloid/Lymphoid I A. Are MLNs relaps B. Is disease positive Yes No If diagnosis is none	a: ave unresectable, locally advanced failed 1 or more prior therapies? Ye ve for a fibroblast growth factor rece Yes No Neoplasms (MLNs): sed or refractory? Yes No ve for a fibroblast growth factor rece ve	eptor 2 (FGFR2) fusion or other FGFR eptor 1 (FGFR1) rearrangement? agnosis:
3. Has the member experier If yes, please specify adverse	evidence of progressive disease who need adverse drug reactions related ereactions:	nile on pemigatinib? Yes No d to pemigatinib therapy? Yes No Date:
the best of my knowledge.		and all information is true and correct to if necessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

Fax: 1-800-224-4014

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 151 2/3/2023